Advertisement
Advertisement
U.S. Markets open in 3 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8604+0.0100 (+1.18%)
At close: 04:00PM EDT
0.9034 +0.04 (+5.00%)
After hours: 07:44PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8504
Open0.8601
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.8500 - 0.9500
52 Week Range0.8200 - 4.3550
Volume394,413
Avg. Volume439,407
Market Cap35.464M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-1.9000
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • GlobeNewswire

    Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

    DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the So

  • GlobeNewswire

    Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

    INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profileDEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th Interna

  • GlobeNewswire

    Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

    DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 2:00 p.m. ET, and host investor meetings. The conference is

Advertisement
Advertisement